Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ: IMNM )

10.97 -0.11 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,453,565
Open 10.94
Bid (Size) 10.85 (5)
Ask (Size) 11.67 (1)
Prev. Close 11.08
Today's Range 10.82 - 11.50
52wk Range 8.330 - 30.96
Shares Outstanding 62,416,845
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Small-Cap Stocks With Big Growth Potential
Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire

Performance

YTD
-0.36%
-0.36%
1 Month
+16.45%
+16.45%
3 Month
-21.64%
-21.64%
6 Month
-8.12%
-8.12%
1 Year
+16.83%
+16.83%

More News

Read More
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Analyst Expectations For Immunome's Future
Via Benzinga
Evaluating Immunome: Insights From 4 Financial Analysts
Via Benzinga
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
From Immunome, Inc.
Via Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
From Immunome, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
From Immunome, Inc.
Via Business Wire
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
From Immunome, Inc.
Via Business Wire
Immunome Appoints Phil Tsai as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.